/STRO
STRO Stock - Sutro Biopharma, Inc.
Healthcare|BiotechnologyNASDAQ
$9.98+11.76%
+$1.05 (+11.76%) • Dec 19
41
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.80
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.55
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-80.0%upside
Target: $2.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for STRO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$9.88 – $10.08
TARGET (TP)$2.00
STOP LOSS$9.18
RISK/REWARD1:-10.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.62
52W High$21.50
52W Low$5.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $62.04M | $153.73M | $67.77M | $61.88M | $42.72M |
| Gross Profit | $54.83M | $146.91M | $59.48M | $52.11M | $-34,239,000 |
| Gross Margin | 88.4% | 95.6% | 87.8% | 84.2% | -80.1% |
| Operating Income | $-238,453,000 | $-89,278,000 | $-128,943,000 | $-98,524,000 | $-71,057,000 |
| Net Income | $-227,461,000 | $-106,793,000 | $-119,204,000 | $-105,538,000 | $-32,128,000 |
| Net Margin | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% |
| EPS | $-29.60 | $-17.80 | $-23.50 | $-22.90 | $-9.90 |
Company Overview
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
43%
Hold / Neutral
3
43%
Sell / Underperform
1
14%
Analyst Consensus🔴 Bearish
3 Bullish4 Neutral/Bearish
Price Targets
$8
Average Target
↓ 22.3% Downside
Now
$1
Low
$8
Average
$15
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| June 16th 2025 | Piper Sandler | Upgrade | Overweight | $2 |
| March 17th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| March 14th 2025 | Citizens JMP | Downgrade | Market Perform | - |
| March 14th 2025 | Wedbush | Downgrade | Neutral | $2← $8 |
| March 14th 2025 | BofA Securities | Downgrade | Underperform | $1← $11 |
| May 8th 2024 | BofA Securities | Initiation | Buy | $12 |
| November 9th 2023 | Deutsche Bank | Initiation | Buy | $12 |
| October 6th 2023 | Oppenheimer | Initiation | Outperform | $10 |
| March 21st 2023 | Wells Fargo | Downgrade | Equal Weight | $8← $15 |
| August 18th 2022 | Wells Fargo | Resumed | Overweight | $15 |
Earnings History & Surprises
STROBeat Rate
50%
Last 18 quarters
Avg Surprise
+4.7%
EPS vs Estimate
Beats / Misses
9/8
1 met exactly
Latest EPS
$-6.70
Q4 2025
EPS Surprise History
Q1 24
+151.2%
$0.42vs$-0.82
Q2 24
-3.3%
$-0.95vs$-0.92
Q3 24
+22.4%
$-0.59vs$-0.76
Q4 24
+20.3%
$-0.59vs$-0.74
Q1 25
-3.5%
$-0.89vs$-0.86
Q2 25
-44.4%
$-0.91vs$-0.63
Q3 25
+64.1%
$-0.14vs$-0.39
Q4 25
-59.5%
$-6.70vs$-4.20
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-4.67 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-4.20 | $-6.70 | -59.5% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.39 | $-0.14 | +64.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.63 | $-0.91 | -44.4% | ✗ MISS |
Q1 2025 | Mar 13, 2025 | $-0.86 | $-0.89 | -3.5% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.74 | $-0.59 | +20.3% | ✓ BEAT |
Q3 2024 | Aug 13, 2024 | $-0.76 | $-0.59 | +22.4% | ✓ BEAT |
Q2 2024 | May 13, 2024 | $-0.92 | $-0.95 | -3.3% | ✗ MISS |
Q1 2024 | Mar 25, 2024 | $-0.82 | $0.42 | +151.2% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.76 | $-0.81 | -6.6% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.73 | $-0.64 | +12.3% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.83 | $-0.76 | +8.4% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.64 | $-0.61 | +4.7% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.15 | $-0.37 | -146.7% | ✗ MISS |
Q3 2022 | Aug 8, 2022 | $-0.74 | $-0.55 | +25.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.79 | $-0.84 | -6.3% | ✗ MISS |
Q1 2022 | Feb 28, 2022 | $-0.67 | $-0.83 | -23.9% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.67 | $-0.67 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $-0.42 | $-0.13 | +69.0% | ✓ BEAT |
Latest News
Sutro Biopharma Regains Nasdaq Compliance
📈 PositiveBenzinga•Dec 17, 2025, 09:06 PM
Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralBenzinga•Dec 3, 2025, 01:55 PM
Sutro Biopharma Doses First Cohort Of Patients In Phase 1 Trial Of STRO-004; Initial Clinical Data Expected Mid 2026
📈 PositiveBenzinga•Dec 3, 2025, 01:03 PM
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
➖ NeutralBenzinga•Dec 3, 2025, 12:50 AM
Sutro Biopharma shares are trading lower after the company announced a 1-for-10 reverse stock split.
📉 NegativeBenzinga•Dec 1, 2025, 05:08 PM
Sutro Biopharma Announces 1-For-10 Reverse Stock Split, Effective Dec. 3
📉 NegativeBenzinga•Dec 1, 2025, 01:04 PM
Sutro Biopharma shares are trading lower after the company reported mixed Q3 financial results.
📉 NegativeBenzinga•Nov 7, 2025, 04:16 PM
Sutro Biopharma Q3 EPS $(0.67) Misses $(0.41) Estimate, Sales $9.693M Beat $9.132M Estimate
➖ NeutralBenzinga•Nov 6, 2025, 10:00 PM
Sutro Biopharma Reveals An Organizational Restructuring To Prioritize The Advancement Of Its Three ADC Programs And Research And Development Collaborations; The Restructuring, Is Expected To Extend The Company's Runway Into At Least Mid-2027; Restructuring To Result In Workforce Reduction Of One-Third Of Employees; Co. On Track To Advance STRO-004 Into Clinic This Year, With Initial Data Expected In 2026
➖ NeutralBenzinga•Sep 29, 2025, 09:14 PM
Frequently Asked Questions about STRO
What is STRO's current stock price?
Sutro Biopharma, Inc. (STRO) is currently trading at $9.98 per share. The stock has moved +11.76% today.
What is the analyst price target for STRO?
The average analyst price target for STRO is $2.00, based on 1 analyst.
What sector is Sutro Biopharma, Inc. in?
Sutro Biopharma, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is STRO's market cap?
Sutro Biopharma, Inc. has a market capitalization of $0.08 billion, making it a small-cap company.
Does STRO pay dividends?
No, Sutro Biopharma, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorADVM
Adverum Biotechnologies, Inc.
$4.36
Mkt Cap: $0.1B
ARTV
Artiva Biotherapeutics, Inc.
$4.74
Mkt Cap: $0.1B
CNTB
Connect Biopharma Holdings Limited
$2.27
Mkt Cap: $0.1B
DTIL
Precision BioSciences, Inc.
$4.49
Mkt Cap: $0.1B
GUTS
Fractyl Health, Inc. Common Stock
$2.20
Mkt Cap: $0.2B
IFRX
InflaRx N.V.
$1.11
Mkt Cap: $0.1B
KLRS
Kalaris Therapeutics Inc
$9.13
Mkt Cap: $0.2B
MGX
Metagenomi, Inc. Common Stock
$1.76
Mkt Cap: $0.1B
PLRX
Pliant Therapeutics, Inc.
$1.23
Mkt Cap: $0.1B
STTK
Shattuck Labs, Inc.
$3.15
Mkt Cap: $0.2B
Explore stocks similar to STRO for comparison